This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Cartalax (20 mg Vial)
Cartalax is a synthetic tripeptide bioregulator (Ala-Glu-Asp; sequence “AED”) developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology[1]. Preclinical studies indicate it may modulate fibroblast proliferation markers (Ki-67), reduce pro-apoptotic signaling (p53, caspase-3), and support extracellular matrix homeostasis[2][3]. Published human evidence for this compound is limited; available descriptions are based on preclinical and observational data for research context only.
Quick Reference
What is Cartalax?
Research overview based on the cited scientific literature.
• Goal: Support connective-tissue homeostasis and fibroblast function based on preclinical bioregulator research[2][3].
• Storage: Lyophilized: refrigerate or freeze; reconstituted: refrigerate; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long-term stability; protect from light and moisture[11].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Cartalax studied?
Cartalax (Ala-Glu-Asp) is classified among the Khavinson bioregulatory peptides—ultrashort peptides that may interact with DNA and modulate gene expression at nanomolar concentrations[1][4]. The peptide sequence corresponds to a motif found in the alpha-1 chain of type XI collagen, a structural protein important for cartilage integrity[5]. In preclinical fibroblast and chondrocyte culture models, Cartalax has been reported to upregulate Ki-67 (a proliferation marker), increase SIRT-1/SIRT-6 expression, reduce p53 and caspase-3 activity (pro-apoptotic signals), and inhibit MMP-9 synthesis (an enzyme linked to extracellular matrix degradation)[2][3][6].
What does the research report about Cartalax?
Observations from preclinical literature.
• May support fibroblast proliferation and reduce markers of cellular senescence in aged cell cultures[2][3].
• Preclinical data suggest modulation of extracellular matrix homeostasis via MMP-9 inhibition and collagen-related gene expression[6].
• General tolerability: Khavinson bioregulator peptides have been described as well tolerated in observational settings; occasional mild injection-site reactions (redness, itch) may occur with subcutaneous administration[1].
• Limitations: No large-scale human RCTs; most data derive from in vitro or rodent models.
Research Limitations / Risk Notes
Published human clinical trial data for subcutaneous Cartalax is limited; this protocol extrapolates from preclinical studies and standard peptide handling practices.
No large-scale human RCTs; most data derive from in vitro or rodent models.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
